Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does OMALIZUMAB Cause Incorrect dose administered by device? 9 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 9 reports of Incorrect dose administered by device have been filed in association with OMALIZUMAB (Omalizumab-igec). This represents 0.0% of all adverse event reports for OMALIZUMAB.

9
Reports of Incorrect dose administered by device with OMALIZUMAB
0.0%
of all OMALIZUMAB reports
0
Deaths
1
Hospitalizations

How Dangerous Is Incorrect dose administered by device From OMALIZUMAB?

Of the 9 reports, 1 (11.1%) required hospitalization.

Is Incorrect dose administered by device Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for OMALIZUMAB. However, 9 reports have been filed with the FAERS database.

What Other Side Effects Does OMALIZUMAB Cause?

No adverse event (9,736) Asthma (9,354) Urticaria (9,231) Off label use (9,199) Dyspnoea (8,323) Drug ineffective (6,747) Cough (5,926) Pruritus (5,224) Fatigue (5,053) Malaise (4,820)

What Other Drugs Cause Incorrect dose administered by device?

EXENATIDE (3,332) EVOLOCUMAB (2,840) SOMATROPIN (2,486) ALBUTEROL (1,236) ETANERCEPT (1,032) SECUKINUMAB (996) ERENUMAB-AOOE (973) BUDESONIDE\FORMOTEROL (753) INSULIN GLARGINE (753) BUDESONIDE\FORMOTEROL\GLYCOPYRROLATE (674)

Which OMALIZUMAB Alternatives Have Lower Incorrect dose administered by device Risk?

OMALIZUMAB vs OMAVELOXOLONE OMALIZUMAB vs OMBITASVIR OMALIZUMAB vs OMBITASVIR\PARITAPREVIR\RITONAVIR OMALIZUMAB vs OMEGA-3-ACID ETHYL ESTERS OMALIZUMAB vs OMEGA-3-CARBOXYLIC ACIDS

Related Pages

OMALIZUMAB Full Profile All Incorrect dose administered by device Reports All Drugs Causing Incorrect dose administered by device OMALIZUMAB Demographics